FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048332638> ?p ?o ?g. }

• W3048332638 endingPage "36" @default.
• W3048332638 startingPage "31" @default.
• W3048332638 abstract "•With only 10 years left to meet the WHO's hepatitis elimination targets, COVID-19 is impacting progress.•A 1-year delay in HCV programs could cause excess HCV morbidity and mortality.•A 1-year delay could cause 72,000 excess deaths from HCV.•Most excess deaths would be in the lower middle income and high-income groups. Background & AimsCoronavirus disease 2019 (COVID-19) has placed a significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in HCV liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination programs.MethodsPreviously developed models were adapted for 110 countries to include a status quo or ‘no delay’ scenario and a ‘1-year delay’ scenario assuming significant disruption in interventions (screening, diagnosis, and treatment) in the year 2020. Annual country-level model outcomes were extracted, and weighted averages were used to calculate regional (WHO and World Bank Income Group) and global estimates from 2020 to 2030. The incremental annual change in outcomes was calculated by subtracting the ‘no-delay’ estimates from the ‘1-year delay’ estimates.ResultsThe ‘1-year delay’ scenario resulted in 44,800 (95% uncertainty interval [UI]: 43,800–49,300) excess hepatocellular carcinoma cases and 72,300 (95% UI: 70,600–79,400) excess liver-related deaths, relative to the ‘no-delay’ scenario globally, from 2020 to 2030. Most missed treatments would be in lower-middle income countries, whereas most excess hepatocellular carcinoma and liver-related deaths would be among high-income countries.ConclusionsThe impact of COVID-19 extends beyond the direct morbidity and mortality associated with exposure and infection. To mitigate the impact on viral hepatitis programming and reduce excess mortality from delayed treatment, policy makers should prioritize hepatitis programs as soon as it becomes safe to do so.Lay SummaryCOVID-19 has resulted in many hepatitis elimination programs slowing or stopping altogether. A 1-year delay in hepatitis diagnosis and treatment could result in an additional 44,800 liver cancers and 72,300 deaths from HCV globally by 2030. Countries have committed to hepatitis elimination by 2030, so attention should shift back to hepatitis programming as soon as it becomes appropriate to do so. Coronavirus disease 2019 (COVID-19) has placed a significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in HCV liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination programs. Previously developed models were adapted for 110 countries to include a status quo or ‘no delay’ scenario and a ‘1-year delay’ scenario assuming significant disruption in interventions (screening, diagnosis, and treatment) in the year 2020. Annual country-level model outcomes were extracted, and weighted averages were used to calculate regional (WHO and World Bank Income Group) and global estimates from 2020 to 2030. The incremental annual change in outcomes was calculated by subtracting the ‘no-delay’ estimates from the ‘1-year delay’ estimates. The ‘1-year delay’ scenario resulted in 44,800 (95% uncertainty interval [UI]: 43,800–49,300) excess hepatocellular carcinoma cases and 72,300 (95% UI: 70,600–79,400) excess liver-related deaths, relative to the ‘no-delay’ scenario globally, from 2020 to 2030. Most missed treatments would be in lower-middle income countries, whereas most excess hepatocellular carcinoma and liver-related deaths would be among high-income countries. The impact of COVID-19 extends beyond the direct morbidity and mortality associated with exposure and infection. To mitigate the impact on viral hepatitis programming and reduce excess mortality from delayed treatment, policy makers should prioritize hepatitis programs as soon as it becomes safe to do so." @default.
• W3048332638 created "2020-08-13" @default.
• W3048332638 creator A5011520858 @default.
• W3048332638 creator A5012919389 @default.
• W3048332638 creator A5018589991 @default.
• W3048332638 creator A5025315719 @default.
• W3048332638 creator A5027828487 @default.
• W3048332638 creator A5031867546 @default.
• W3048332638 creator A5040002369 @default.
• W3048332638 creator A5041520897 @default.
• W3048332638 creator A5045504446 @default.
• W3048332638 creator A5049828572 @default.
• W3048332638 creator A5050093133 @default.
• W3048332638 creator A5051956323 @default.
• W3048332638 creator A5053329115 @default.
• W3048332638 creator A5067681635 @default.
• W3048332638 date "2021-01-01" @default.
• W3048332638 modified "2023-10-18" @default.
• W3048332638 title "Impact of COVID-19 on global HCV elimination efforts" @default.
• W3048332638 cites W2137401503 @default.
• W3048332638 cites W2578013986 @default.
• W3048332638 cites W3010223921 @default.
• W3048332638 cites W3016794338 @default.
• W3048332638 doi "https://doi.org/10.1016/j.jhep.2020.07.042" @default.
• W3048332638 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7411379" @default.
• W3048332638 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32777322" @default.
• W3048332638 hasPublicationYear "2021" @default.
• W3048332638 type Work @default.
• W3048332638 sameAs 3048332638 @default.
• W3048332638 citedByCount "171" @default.
• W3048332638 countsByYear W30483326382020 @default.
• W3048332638 countsByYear W30483326382021 @default.
• W3048332638 countsByYear W30483326382022 @default.
• W3048332638 countsByYear W30483326382023 @default.
• W3048332638 crossrefType "journal-article" @default.
• W3048332638 hasAuthorship W3048332638A5011520858 @default.
• W3048332638 hasAuthorship W3048332638A5012919389 @default.
• W3048332638 hasAuthorship W3048332638A5018589991 @default.
• W3048332638 hasAuthorship W3048332638A5025315719 @default.
• W3048332638 hasAuthorship W3048332638A5027828487 @default.
• W3048332638 hasAuthorship W3048332638A5031867546 @default.
• W3048332638 hasAuthorship W3048332638A5040002369 @default.
• W3048332638 hasAuthorship W3048332638A5041520897 @default.
• W3048332638 hasAuthorship W3048332638A5045504446 @default.
• W3048332638 hasAuthorship W3048332638A5049828572 @default.
• W3048332638 hasAuthorship W3048332638A5050093133 @default.
• W3048332638 hasAuthorship W3048332638A5051956323 @default.
• W3048332638 hasAuthorship W3048332638A5053329115 @default.
• W3048332638 hasAuthorship W3048332638A5067681635 @default.
• W3048332638 hasBestOaLocation W30483326381 @default.
• W3048332638 hasConcept C118552586 @default.
• W3048332638 hasConcept C126322002 @default.
• W3048332638 hasConcept C144024400 @default.
• W3048332638 hasConcept C149923435 @default.
• W3048332638 hasConcept C166957645 @default.
• W3048332638 hasConcept C205649164 @default.
• W3048332638 hasConcept C27415008 @default.
• W3048332638 hasConcept C2776455275 @default.
• W3048332638 hasConcept C2777075537 @default.
• W3048332638 hasConcept C2778019345 @default.
• W3048332638 hasConcept C2779134260 @default.
• W3048332638 hasConcept C2779343474 @default.
• W3048332638 hasConcept C2780664029 @default.
• W3048332638 hasConcept C44249647 @default.
• W3048332638 hasConcept C71924100 @default.
• W3048332638 hasConceptScore W3048332638C118552586 @default.
• W3048332638 hasConceptScore W3048332638C126322002 @default.
• W3048332638 hasConceptScore W3048332638C144024400 @default.
• W3048332638 hasConceptScore W3048332638C149923435 @default.
• W3048332638 hasConceptScore W3048332638C166957645 @default.
• W3048332638 hasConceptScore W3048332638C205649164 @default.
• W3048332638 hasConceptScore W3048332638C27415008 @default.
• W3048332638 hasConceptScore W3048332638C2776455275 @default.
• W3048332638 hasConceptScore W3048332638C2777075537 @default.
• W3048332638 hasConceptScore W3048332638C2778019345 @default.
• W3048332638 hasConceptScore W3048332638C2779134260 @default.
• W3048332638 hasConceptScore W3048332638C2779343474 @default.
• W3048332638 hasConceptScore W3048332638C2780664029 @default.
• W3048332638 hasConceptScore W3048332638C44249647 @default.
• W3048332638 hasConceptScore W3048332638C71924100 @default.
• W3048332638 hasIssue "1" @default.
• W3048332638 hasLocation W30483326381 @default.
• W3048332638 hasLocation W30483326382 @default.
• W3048332638 hasLocation W30483326383 @default.
• W3048332638 hasOpenAccess W3048332638 @default.
• W3048332638 hasPrimaryLocation W30483326381 @default.
• W3048332638 hasRelatedWork W1966954097 @default.
• W3048332638 hasRelatedWork W1967442145 @default.
• W3048332638 hasRelatedWork W1982676366 @default.
• W3048332638 hasRelatedWork W2054405008 @default.
• W3048332638 hasRelatedWork W2057741435 @default.
• W3048332638 hasRelatedWork W2387336199 @default.
• W3048332638 hasRelatedWork W2933788635 @default.
• W3048332638 hasRelatedWork W2938717725 @default.
• W3048332638 hasRelatedWork W30752394 @default.
• W3048332638 hasRelatedWork W3160829853 @default.
• W3048332638 hasVolume "74" @default.
• W3048332638 isParatext "false" @default.

• next